Drug Profile
Vinorelbine/Cisplatin - Qrono
Alternative Names: QR 210Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Qrono
- Class Antineoplastics; Platinum complexes; Small molecules; Vinca alkaloids
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral, Injection)
- 16 Aug 2017 Chemical structure information added
- 03 Aug 2017 Vinorelbine/Cisplatin- Qrono is available for licensing as of 03 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)